AstraZeneca's new drug for rare diseases, Vonovi, has been approved.

On December 25th, it was learned from AstraZeneca that the company's joint development with Ionis Pharmaceuticals, Waylivra, has been officially approved in China for the treatment of adult patients with hereditary transthyretin amyloidosis polyneuropathy. Ipatasertib sodium is the first and currently the only genetically-silenced agent approved in China for the treatment of ATTRv-PN.